Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat
Launched by KYTHERA BIOPHARMACEUTICALS · Feb 8, 2008
Trial Information
Current as of July 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Submental fat that was considered undesirable by the subject and graded by the investigator as 2 or 3 using the submental fat (SMF) rating scale
- • Good general health
- • Signed informed consent
- Exclusion Criteria:
- • History of any treatment in the neck or chin area
- • Loose skin or prominent platysmal bands in the neck or chin area
- • Recent treatment with anticoagulants
- • Presence of clinically significant health problems
About Kythera Biopharmaceuticals
Kythera Biopharmaceuticals is a clinical-stage biotechnology company dedicated to the development of innovative aesthetic treatments that enhance the quality of life for patients. Focused on addressing unmet needs in the aesthetic medicine market, Kythera leverages advanced scientific research and technology to create targeted therapies. With a commitment to rigorous clinical trials and regulatory standards, the company aims to deliver safe and effective solutions that empower individuals to achieve their desired appearance. Through its expertise in biopharmaceutical development, Kythera is poised to make significant contributions to the field of aesthetic medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toorak, Victoria, Australia
Sydney, , Australia
Niagara Falls, Ontario, Canada
Oakville, Ontario, Canada
Toronto, Ontario, Canada
Manchester, , United Kingdom
Patients applied
Trial Officials
Frederick Beddingfield, III, M.D., Ph.D.
Study Director
Kythera Biopharmaceuticals, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials